Radhakrishnan Ramchandren MD

PubMed

• 12 citations
  Cardiac Amyloid Detection by PET/CT Imaging of Iodine (I) Evuzamitide (I-p5+14): A Phase 1/2 Study.
  Jonathan S Wall, Emily B Martin, Ronald Lands, Radhakrishnan Ramchandren, Alan Stuckey
  JACC. Cardiovascular Imaging. 2023-11-01
• 10 citations
  The iRregimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
  Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna
  Eclinicalmedicine. 2023-02-01
• Editorial: Advances in the treatment of Hodgkin lymphoma.
  Matthew Mei, Guilherme Perini, Radhakrishnan Ramchandren
  Frontiers in Oncology. 2023-01-01

Journal Articles

• Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma  
  Patrick B. Johnston, Radhakrishnan Ramchandren, Lauren C. Pinter-Brown, BioMed Central

Abstracts/Posters

• Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124I-p5+14, for Imaging Systemic Amyloidosis
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018